Citigroup’s Day One Biopharmaceuticals DAWN Stock Holding History

Citigroup’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.47M	Buy	115,000 +15,000	+15%	+$211K	﹤0.01%	2533
2025 Q4	$932K	Buy	+100,000	New	+$835K	﹤0.01%	3185
2025 Q3	–	Sell	-62,000	Closed	-$403K	–	6135
2025 Q2	$403K	Hold	62,000	–	–	﹤0.01%	3748
2025 Q1	$492K	Sell	62,000 -24,900	-29%	-$268K	﹤0.01%	3692
2024 Q4	$1.1M	Buy	86,900 +27,000	+45%	+$376K	﹤0.01%	3292
2024 Q3	$834K	Buy	59,900 +29,900	+100%	+$427K	﹤0.01%	3404
2024 Q2	$413K	Buy	+30,000	New	+$439K	﹤0.01%	3511

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Citigroup's DAWN Position: Q1 2026 in Review

Citigroup reduced its Day One Biopharmaceuticals (DAWN) stake by 43% in Q1 2026, selling an estimated $144K and leaving 13,848 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #3806.

Citigroup first reported a position in DAWN in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.83M in Q1 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Citigroup held 13,848 shares of Day One Biopharmaceuticals worth $297K as of Q1 2026.
Citigroup sold 10,246 Day One Biopharmaceuticals shares in Q1 2026, an estimated $144K.
Day One Biopharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3806 holding.
Citigroup first reported a position in Day One Biopharmaceuticals in Q3 2021 and has held it in 19 quarters since.
Citigroup's Day One Biopharmaceuticals position peaked at $2.83M in Q1 2024.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.